Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: Tolerance and outcome

Archives of Internal Medicine

Volumn 156, Issue 8, 1996, Pages 882-888

  Ibrahim, Nuhad K ^a   Frye, Debra K ^a   Buzdar, Aman U ^a   Walters, Ronald S ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BACTERIAL VACCINE; BCG VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; LEVAMISOLE; METHOTREXATE; PEPTICHEMIO; TAMOXIFEN; TEGAFUR; THIOTEPA; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MEGADOSE; FEVER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PSEUDOGENE; PSEUDOMONAS; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BREAST NEOPLASMS; CAUSE OF DEATH; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029996460     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.8.882     Document Type: Article

References (71)

1. Samet JS, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385-3390.
2. Silliman RA, Balducci L, Goodwin J, et al. Breast cancer care in old age: what we know, don't know, and do. J Natl Cancer Inst 1993,85.190-199.
3. Baldwin L, Schapira DV, Cox CE, et al Breast cancer of the older woman: an annotated review. J Am Geriatr Soc. 1991,39:1113-1123.
4. DeVita VT Jr. Opening remarks. In: Yancik R, ed Perspectives on Prevention and Treatment of Cancer in the Elderly. New York, NY: Raven Press; 1983;24:1-3.
5. Carbone PP, Begg BC, Jensen L, et al. Oncology perspective on breast cancer in the elderly. In. Yancik R, ed Perspectives on Prevention and Treatment of Cancer in the Elderly New York, NY: Raven Press; 1983;24:63-71.
6. Fentiman IS. Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet. 1990;335:1020-1022
7. Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship between age at diagnosis and treatments received by cancer patients J Am Geriatr Soc. 1985; 33:585-589
8. Donegan WL Treatment of breast cancer in the elderly. In: Yancik R, ed. Perspectives on Prevention and Treatment of Cancer in the Elderly. New York, NY: Raven Press; 1983,24 83-96
9. Yancik R. Frame of reference: old age as the contest for the prevention and treatment of cancer. In: Yancik R, ed. Perspectives on Prevention ana Treatment of Cancer in the Elderly New York, NY: Raven Press; 1983,24:5-18
10. Kane RA. Coordination of cancer treatment and social support for the elderly. In: Yancik R, ed. Perspectives on Prevention and Treatment of Cancer in the Elderly. New York, NY: Raven Press; 1983;24:227-238
11. Levy SM. The aging cancer patient: behavioral research issues. In: Yancik R, ed. Perspectives on Prevention and Treatment of Cancer in the Elderly New York, NY. Raven Press; 1983;24.239-248.
12. Rimer B, Jones W, Wilson C, et al. Planning a cancer control program for older citizens. Serontologist. 1983;4:384-389.
13. Muggia FM, Blum RH. Cancer treatment and age-dependent considerations. In: Yancik R, ed. Perspectives on Prevention and Treatment of Cancer in the Elderly New York, NY: Raven Press; 1983;24:239-248.
14. Greenfield S, Blanco D, Elashoff R, et al. Patterns of care related to age of breast cancer patients. JAMA 1987,257:2766-2770.
15. Yancik R, Kessler L, Yates JW The elderly population: opportunities for cancer prevention and detection. Cancer. 1988;62(suppl 8):1823-1828.
16. Goodwin JS Knowledge about aging among physicians. J Aging Health. 1989, 1 234-243.
17. Walsh S, Begg C, Carbone P. Cancer chemotherapy in the elderly. Semin Oncol. 1989;16:66-75.
18. Begg CB, Carbone PP Clinical trials and drug toxicity in the elderly. Cancer. 1983;52 1986-1992
19. Begg CB, Elson PJ, Carbone PP. A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols. In: Yancik R, ed. Cancer in the Elderly: Approaches to Early Detection and Treatment. Berlin, Germany. Springer-Verlag; 1989:149-163
20. Hoagland HC. Hematologic complications of cancer chemotherapy Semin Oncol. 1982;9:95-102.
21. Wetle T. Age as a risk factor for inadequate treatment. JAMA. 1987;258:516.
22. Riley MW Cancer and the life course. In. Yancik R, ed. Perspectives on Prevention and Treatment of Cancer in the Elderly. New York, NY. Raven Press; 1983;24.25-32.
23. Christman K, Muss HB, Case LD, et al Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA. 1992;268:57-62.
24. Taylor SG, Gelman RS, Falkson G, et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV cancer in elderly women. Ann Intern Med. 1986;104:455-461
25. Burklow J. Doctors concerned about age bias in cancer treatment J Natl Cancer Inst 1992,84:391
26. Early Breast Cancer Trialists's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet. 1992,339:1-15, 71-85.
27. Hankey BF, Ries LAG, Miller BA, Kosaey CL. Overview, PI.10. In: Miller BA, Ries LAG, Hankey BF, et al, eds. Cancer Statistics Review. 1973-1989. Bethesda, Md: National Cancer Institute, 1992 National Institutes of Health publication 92-2789.
28. Blumenschein GR, Cardenas JO, Freireich EJ, Gottlieb JA. FAC combination chemotherapy for metastatic breast cancer. Proc Am Assoc Cancer Res. 1974, 15:193. Abstract.
29. Hortobagyi GN, Gutterman JU, Blumenschein GR, et al. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG. Cancer. 1979;43:1225-1233.
30. Hortobagyi GN, Blumenschein GR, Buzdar AU, et al. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer. the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981,18:163-172.
31. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guérm Cancer Treat Rep. 1978;62:685-1692.
32. Hortobagyi GN, Gutterman JU, Blumenschein GR, et al. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and tevamisole. Cancer. 1979;43.1112-1122
33. Blumenschein GR, Hortobagyi GN, Richman SP, et al. Alternating noncrossresistant combination chemotherapy and active nonspecific immunotherapy with BCF or MER BCG for advanced breast carcinoma Cancer. 1980,45:742-749.
34. Hortobagyi GN, Blumenschein GR, Tashima CK, et al Ftorafur, Adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer Cancer. 1979;44:398-405.
35. Buzdar AU, Legha SS, Tashima CK, et al. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 1979;63:115-120
36. Hortobagyi GN, Buzdar AU, Bodey GP, et al High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 1987;5.178-184.
37. Hortobagyi GN, Yap HY, Wiseman CL, et al. Chemoimmunotherapy for metastalic breast cancer with 5-FU, Adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum and Pseudomonas vaccine. Cancer Treat Rep 1980;64 157-159.
38. Legha SS, Blumenschein SR, Hortobagyi GN, Buzdar AU, Yap HY, Bodey GP. Treatment of metastatic breast carcinoma causing a combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and tamoxifen. Proceedings of the 18th Annual Meeting of the American Society for Clinical Oncology; April 25-27, 1982, St Louis, Mo. Abstract C-299
39. Hortobagyi GN, Bodey GP, Buzdar AU, et al Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987;5:354-364.
40. Legha SS, Wang YM, Mackay B, et al. Clinical and pharmacological investigation of the effects of tocopherol on Adriamycin cardiotoxicity Ann N Y Acad Sci. 1982,33 411-418.
41. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combined chemotherapy of metastatic breast carcinoma with cyclophosphamide, Adriamycin and peptichemio Cancer. 1984,53:1836-1840.
42. Theriault RL, Hortobagyi GN, Kau SW, et al. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer 1988;62:2105-2110.
43. Hortobagyi GN, Buzdar AU, Frye D, et al. Combined antiestrogen and cytotoxic therapy with Pseudomonas vaccine immnotherapy for metastatic breast cancer. a prospective, random trial Cancer 1987;60:2596-2604.
44. Hortobagyi GN, Frye D, Buzdar AU, et al Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast cancer. Cancer. 1989;63:37-45.
45. Buzdar AU, Yap HY, Esparza L, et al. A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer. Int J Exp Clin Chemother. 1988;1:48-55.
46. Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979;39:1552-1562.
47. Allen C, Cox E, Manton K, et al. Breast cancer in the elderly: current patterns of care. J Am Geriatr Soc. 1986;34:637-642
48. Turnbull A, Gundy E, Howland W, et al. Surgical mortality among the elderly: an analysis of 4,050 operations (1970-1974). Clin Bull. 1978;8:139-142.
49. Fox S, Murata P, Stein J. The impact of physician compliance on screening mammography for older women Arch Intern Med. 1991;151:50-56
50. Herbsman H, Feldman J, Seldera J, et al. Survival following breast cancer surgery in the elderly. Cancer. 1981;47:2358-2363.
51. Kennedy BJ. Clinical oncology: focus on the elderly. In: Yancik R, ed. Perspectives on Prevention and Treatment of Cancer in the Elderly New York, NY: Raven Press, 1983;24:43-50
52. Chu J, Diehr P, Feigi P, et al. The effect of age on the care of women with breast cancer in community hospitals. J Gerontol 1987,42:185-190.
53. Silliman RA, Guadagnoli E, Weitberg A, et al Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989;44:M46-M50.
54. Goodwin JS, Samet JM. Care received by older women diagnosed with breast cancer. Cancer Control: J Moffitt Cancer Center 1994;1:313-319.
55. International Cancer Research Data Bank of the National Cancer Institute. Compilation of Experimental Cancer Therapy Protocol Summaries. Washington, DC. US Dept of Health and Human Services, 1981 1-51. Publication (NIH) 81-1116.
56. Hoogstraten B, George SL, Samal B, et al. Combination chemotherapy and Adriamycin in patients with advanced breast cancer. Cancer. 1976;38:13-20
57. Tormey DC, Weinberg VE, Holland JF, et al. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer J Clin Oncol 1983;1:138-145.
58. Brincker H. Rose C, von der Maase H, Drubernowsky P. A randomized study of CAF + TAM (tamoxifen) versus CMF + TAM in metastatic breast cancer. Proc Am Soc Clin Oncol. 1984;3:113.
59. Aisner J, Weinberg V, Perloff M, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each plus-minus MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol. 1987;5:1523.
60. Tormey DC, Weinberg VE, Leone LA, et al A comparison of intermittent vs. continuous and of Adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol. 1984;7:231.
61. Smaltey RV, LeFante J, Baetolnici A, et al A comparison of Cytoxan, Adriamycin and 5-FU (CAF) + Cytoxan, methotrexate, 5-FU, vincristine and prednisone (CMFVP) in patients with advanced breast cancer: a Southwestern Cancer Study Group project Breast Cancer Res Treat 1983,3:209-220.
62. Bull J, Tormey D, Li SH, et al. A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy. Cancer 1978;41:1649-1657.
63. Muss HB, White DR, Richards F III, et al Adriamycin versus methotrexate in 5-drug combination chemotherapy for advanced breast cancer. Cancer. 1978; 42 2141-2148.
64. Falkson G, Gelman RS, Tormey DC, et al The Eastern Cooperative Oncology Group experience with cyclophosphamide, Adriamycin and f-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 1985;56:219.
65. Tormey DG, Gelman R, Band PR, et al Comparison of induction chemotherapies for metastatic breast cancer Cancer. 1982,50:1235-1244.
66. Rosen PP, Lesser ML, Kinne DW Breast carcinoma at the extremes of age: a comparison of patients younger than 35 years and older than 75 years J Surg Oncol. 1985;28:90-96.
67. Adami HO, Malker B, Meirik O, et al. Age as a prognostic factor in breast cancer. Cancer. 1985;56:898-902.
68. Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559-563
69. Mueller CB, Ames F, Anderson GD. Breast cancer in 3558 women age as a significant determinant in the rate of dying and the cause of death Surgery. 1978,83:123-132
70. Holland JC, Massie MJ Psychosocial aspects of cancer in the elderly Clin Genatr Med. 1987;3:533-539.
71. Lipschitz DA Age-related decline in hematopoietic reserve capacity Semin Oncol. 1995,22(1, suppl 1):3-5.